Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
evorpacept + trastuzumab + ramucirumab + paclitaxel
- Development stage
- Phase 3
- Lead developer
- ALX Oncology
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A four-drug combination therapy consisting of **evorpacept** (a CD47-blocking fusion protein), **trastuzumab** (a monoclonal antibody against HER2), **ramucirumab** (a monoclonal antibody antagonist of VEGFR-2), and **paclitaxel** (a microtubule-stabilizing chemotherapy). Each agent contributes via a distinct mechanism with the goal of synergistic antitumor activity: Evorpacept promotes antibody-mediated phagocytosis and enhances immune response; trastuzumab inhibits HER2 signaling and mediates immune effector functions; ramucirumab blocks angiogenesis by targeting VEGFR-2; and paclitaxel disrupts microtubule function to inhibit cell division and induce apoptosis. This combination is under investigation primarily in HER2-positive, advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer.
02
Targets
CD47 (Cluster of Differentiation 47)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on evorpacept + trastuzumab + ramucirumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on evorpacept + trastuzumab + ramucirumab + paclitaxel.